| Nov 14 |
IGC Pharma GAAP EPS of -$0.02 beats by $0.01, revenue of $0.41M beats by $0.21M
|
| Nov 14 |
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
|
| Nov 6 |
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
|
| Oct 17 |
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
|
| Oct 3 |
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
|
| Sep 18 |
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
|
| Sep 4 |
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
|
| Aug 26 |
IGC Announces Results of its 2024 Annual Stockholders Meeting
|
| Aug 22 |
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
|
| Aug 20 |
IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
|
